These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34548321)

  • 1. First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.
    Yap TA; Vieito M; Baldini C; Sepúlveda-Sánchez JM; Kondo S; Simonelli M; Cosman R; van der Westhuizen A; Atkinson V; Carpentier AF; Löhr M; Redman R; Mason W; Cervantes A; Le Rhun E; Ochsenreither S; Warren L; Zhao Y; Callies S; Estrem ST; Man M; Gandhi L; Avsar E; Melisi D
    Clin Cancer Res; 2021 Dec; 27(24):6666-6676. PubMed ID: 34548321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy and radiotherapy for advanced pancreatic cancer.
    Haggstrom L; Chan WY; Nagrial A; Chantrill LA; Sim HW; Yip D; Chin V
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD011044. PubMed ID: 39635901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
    Hamilton EP; Falchook GS; Wang JS; Fu S; Oza AM; Imedio ER; Kumar S; Ottesen L; Mugundu GM; de Bruin EC; O'Connor MJ; Jones SF; Spigel DR; Li BT
    Target Oncol; 2024 Nov; 19(6):879-892. PubMed ID: 39487373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.
    Chen XC; Jiao DC; Qiao JH; Wang CZ; Sun XF; Lu ZD; Li LF; Zhang CJ; Yan M; Wei Y; Chen B; Feng YQ; Deng M; Ma MD; Plichta JK; He YW; Liu ZZ
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39612919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H; Greillier L; Cropet C; Bylicki O; Monnet I; Audigier-Valette C; Falchero L; Vergnenègre A; Demontrond P; Geier M; Guisier F; Hominal S; Locher C; Corre R; Chouaid C; Ricordel C;
    Lancet Respir Med; 2024 Oct; ():. PubMed ID: 39486424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China].
    Du J; Qiu X; Ni JY; Wang QL; Tong F; Sha HZ; Zhu YH; Qi L; Cai W; Gao C; Wei XW; Chen MB; Qian ZY; Cai MH; Tao M; Wang CL; Zheng GC; Jiang H; Dai AW; Wu J; Zhao MH; Li XQ; Lu B; Wang CB; Liu BR
    Zhonghua Zhong Liu Za Zhi; 2024 Nov; 46(11):1038-1048. PubMed ID: 39622736
    [No Abstract]   [Full Text] [Related]  

  • 10. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With
    Sweis RF; Gajate P; Morales-Barrera R; Lee JL; Necchi A; de Braud F; Penel N; Grünwald V; Maruzzo M; Meran J; Ishida TC; Bao W; Zhou Y; Ellinghaus P; Rosenberg JE
    JAMA Oncol; 2024 Nov; 10(11):1565-1570. PubMed ID: 39298147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors.
    Lenz HJ; Argilés G; de Jonge MJA; Yaeger R; Doi T; El-Khoueiry A; Eskens F; Kuboki Y; Bertulis J; Nazabadioko S; Pronk L; Tabernero J
    ESMO Open; 2024 Nov; 9(11):103729. PubMed ID: 39617530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.
    File DM; Abdou Y; Force J; Moore DT; Anders CK; Reeder-Hayes K; Carey LA; Muss HB; Perou CM; Marcom PK; Dees EC
    Clin Breast Cancer; 2024 Dec; 24(8):683-690. PubMed ID: 39217059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma.
    Wei M; Liu R; Xu Y; Chen X; Liu C; Bai X; Zhang X; Gao S; Li J; Sheng Z; Lian J; Wang W; Zhang J; Shi S; Xu J; Yu X
    BMC Med; 2024 Sep; 22(1):365. PubMed ID: 39232761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I dose escalation study of the LRP5 antagonist BI 905681 in patients with advanced and metastatic solid tumors.
    Spigel DR; Wang JS; Pronk L; Muskens B; Teufel M; Bashir B; Burris H
    ESMO Open; 2024 Nov; 9(11):103730. PubMed ID: 39617535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Desai KB; Serritella AV; Stadler WM; O'Donnell PH; Sweis RF; Szmulewitz RZ
    Clin Cancer Res; 2024 Jun; 30(11):2384-2392. PubMed ID: 38536082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
    Iyer SP; Sica RA; Ho PJ; Prica A; Zain J; Foss FM; Hu B; Beitinjaneh A; Weng WK; Kim YH; Khodadoust MS; Huen AO; Williams LM; Ma A; Huang E; Ganpule A; Nagar SD; Sripakdeevong P; Cullingford EL; Karnik S; Dequeant ML; Patel JN; He XS; Li Z; He QA; Mendonez JH; Keegan A; Horwitz SM
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39617017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT.
    Coulton S; Nizalova O; Pellatt-Higgins T; Stevens A; Hendrie N; Marchand C; Vass R; Deluca P; Drummond C; Ferguson J; Waller G; Newbury-Birch D
    Public Health Res (Southampt); 2023 Mar; 11(3):1-77. PubMed ID: 37254608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD007807. PubMed ID: 32851663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.